NFE2L2 and Myocardial fibrosis: Li et al. demonstrated that in diabetic mice, the use of empagliflozin suppressed oxidative stress and myocardial fibrosis by inhibiting the transforming growth factor-beta (TGF-beta/Smad) pathway and activating the nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2/ARE) signaling [23].